Pristinamycin: Difference between revisions
m Protected "Pristinamycin": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)) |
m Robot: Automated text replacement (-{{reflist}} +{{reflist|2}}, -<references /> +{{reflist|2}}, -{{WikiDoc Cardiology Network Infobox}} +) |
||
| Line 41: | Line 41: | ||
==Footnotes== | ==Footnotes== | ||
<div class="references-small"> | <div class="references-small">{{reflist|2}}</div> | ||
{{Macrolides, lincosamides and streptogramins}} | {{Macrolides, lincosamides and streptogramins}} | ||
Revision as of 14:02, 6 September 2012
| Clinical data | |
|---|---|
| ATC code | |
| Identifiers | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
|
WikiDoc Resources for Pristinamycin |
|
Articles |
|---|
|
Most recent articles on Pristinamycin Most cited articles on Pristinamycin |
|
Media |
|
Powerpoint slides on Pristinamycin |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Pristinamycin at Clinical Trials.gov Trial results on Pristinamycin Clinical Trials on Pristinamycin at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Pristinamycin NICE Guidance on Pristinamycin
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Pristinamycin Discussion groups on Pristinamycin Patient Handouts on Pristinamycin Directions to Hospitals Treating Pristinamycin Risk calculators and risk factors for Pristinamycin
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Pristinamycin |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Pristinamycin (INN), also spelled pristinamycine, is an antibiotic used primarily in the treatment of staphylococcal infections, and to a lesser extent streptococcal infections. It is a streptogramin group antibiotic, similar to virginiamycin, derived from the bacterium Streptomyces pristina spiralis. It is marketed in Europe by Sanofi-Aventis under the trade name Pyostacine.
Pristinamycin is a mixture of two components that have a synergistic antibacterial action. Pristinamycin I is a macrolide, and results in pristinamycin having a similar spectrum of action to erythromycin. Pristinamycin II is a depsipeptide.[1]
Clinical use
Despite the macrolide component, it is effective against erythromycin-resistant staphylococci and strepcococci.[2][3] Importantly, it is active against methicillin-resistant Staphylococcus aureus (MRSA). Its usefulness for severe infections, however, may be limited by the lack of an intravenous formulation owing to its poor solubility.[4] Nevertheless it is sometimes used as an alternative to rifampicin+fusidic acid or linezolid for the treatment of MRSA.
The lack of an intravenous formulation led to the development of the pristinamycin-derivative quinupristin/dalfopristin, which may be administered intravenously for more severe MRSA infections.
See also
Footnotes
- ↑ Hamilton-Miller J (1991). "From foreign pharmacopoeias: 'new' antibiotics from old?". J Antimicrob Chemother. 27 (6): 702–5. PMID 1938680.
- ↑ Weber P (2001). "[Streptococcus pneumoniae: lack of emergence of pristinamycin resistance]". Pathol Biol (Paris). 49 (10): 840–5. PMID 11776696.
- ↑ Leclercq R, Soussy C, Weber P, Moniot-Ville N, Dib C (2003). "[In vitro activity of the pristinamycin against the isolated staphylococci in the french hospitals in 1999-2000]". Pathol Biol (Paris). 51 (7): 400–4. PMID 12948760.
- ↑ Edited by Sean C. Sweetman, ed. (November 30, 2004). Martindale: The complete drug reference (34th edition ed.). London: Pharmaceutical Press. ISBN 0-85369-550-4.
- Pages with script errors
- CS1 maint: Multiple names: authors list
- CS1 maint: Extra text: editors list
- CS1 maint: Extra text
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Infobox drug articles without a structure image
- Chemical articles without CAS registry number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Antibiotics